New drug tested to stop prostate Cancer's return
NCT ID NCT06555796
Summary
This early-stage study is testing the safety and initial effectiveness of an experimental drug called xaluritamig. It involves about 50 men whose prostate cancer has started to return (shown by rising PSA levels) but hasn't spread to other body parts. The main goal is to see if the drug is safe and if it can control the cancer's progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cabrini Hospital
Malvern, Victoria, 3144, Australia
-
Chris OBrien Lifehouse
Camperdown, New South Wales, 2050, Australia
-
Fred Hutchinson Cancer Center
Seattle, Washington, 98109, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Minnesota Medical Center Fairview
Minneapolis, Minnesota, 55455, United States
-
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390, United States
Conditions
Explore the condition pages connected to this study.